Abstract BACKGROUND Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of sprifermin involve chondrocyte proliferation and extracellular matrix (ECM) production. To gain further insight into the process of sprifermin in the cartilage tissue, this study aimed […]
Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo.
December 12, 2017
J Transl Med